Review of NICE Technology Appraisal Guidance No.219; Everolimus for the second-line treatment of metastatic renal cell carcinoma
Decision to defer the review
As you may be aware the planned date for review of the above guidance is February 2013.
This is the date at which the Institute decides whether sufficient new evidence has emerged for the Appraisal Committee to be asked to undertake a full review appraisal.
Following discussions with the manufacturer of everolimus during the development of a review proposal, we have decided to defer the consideration of the review until more information becomes available from the manufacturer in order to allow a full deliberation of the evidence.
March 2013